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using an algorithm utilizing enrolment records and ICD-9 codes. A patient flow
algorithm was constructed to define treatment cohorts. Patients were stratified
based on the lung cancer drug treatment received following diagnosis and first line
therapy. Total costs are report for the 1 year follow up period after initiation of drug
treatment. RESULTS: A total of 2739 lung cancer patients were included in the
analysis; 53% 65 yr. Paclitaxel or docetaxel plus platinum were the most com-
monly utilized 1st line regimens. Pemetrexed plus docetaxel was the most com-
mon 2nd line treatment. Among patients receiving 1st line treatment and remain-
ing enrolled in the health plan, only 16.7% received 2nd line treatment. Total costs
(average / SD) in the year following chemotherapy initiation was $70,205 
66,956 (range $50,000-$120,000) for those with 1 line of therapy versus $93,432
$66,208 (range $62,000-$169,000) with two or more lines. For all patients, average
ambulatory care costs (which included IV administration costs) were
$34,44940,847, intravenous drug costs ($17,246 27,488), and inpatient hospital
costs (14,180 $31,409) comprised the largest proportion of costs in the year fol-
lowing chemotherapy initiation. CONCLUSIONS: In this analysis, few lung cancer
patients received 2nd line treatment.. For those patients who received 2nd line
treatment and beyond, direct medical care costs are over $23,000 higher over years
2006-10 compared to those receiving only one line. Ambulatory costs comprised
the greatest proportion of total costs (50%).
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OBJECTIVES: To compare health care resource utilization (HRU) and costs by line of
therapy (LOT) among patients with metastatic breast cancer (MBC). METHODS:
MarketScan® databases, January 1, 2005 to December 31, 2009, were used to iden-
tify women aged 18 with breast cancer (ICD-9-CM of 174.xx). The index date was
the first prescription fill or administration of anti-neoplastic agents. Either a 90-day
gap in treatment or initiation of a new regimen ended each LOT. Per patient per
month (PPPM) expenditures for utilizers of inpatient (IP), outpatient (OP), emer-
gency department visits (ED), MBC-drugs (oral and infused), hormonal, radiology,
and supportive therapies across four LOTs (1L-first line, 2L-second, 3L-third, 4L-
fourth) were statistically compared. HRU rates (Visits per patient with 1 Visit)
were also compared. RESULTS: A total of 8494 MBC patients (1L:7,765; 2L:4,077;
3L:2,033, 4L:1,059) were included. Bone metastases were most common (43.9%) at
index followed by liver (17.7%) and lung (12.8%). PPPM expenditures for IP (1L:
$1,183, 2L:$1,318, 3L: $1,401, 4L:$1,670; p0.660), OP (1L:$1,751, 2L:$1,624; 3L: $1,626;
4L:$1,626, p0.413), and ED (1L:$64, 2L:$67, 3L: $73, 4L:$57 p0.997) were not stas-
tically siginificantly different across the four LOTs. PPPM expenditures for MBC
oral-drugs (1L:$460, 2L:$530, 3L:$589, 4L:$743,p0.37), hormonal (1L:$87 , 2L:$65, 3L:
$70, and 4L:$55,p0.388), and radiology therapies (1L:$290,2L:$280,3L: $280,and 4L:
$271, p0.999) were also not statistically different across LOTs. MBC infused-drugs
(1L:$4096,2L:$4,607,3L:$4,841, 4L:$4,521,p0.001) did differ. Within supportives,
PPPM across LOTs were stastically different for anti-emetics (1L:$283,2L:$321;3L:
$320;4L:$311,p0.007) and pain medications (1L:$42,2L:$50;3L:$62;4L:$71,p0.002)
but not for IV-bisphosphonates (1L:$406,2L:$412;3L:$419;4L:$410,p0.964). The
mean HRU rates for IP (range1.4-1.4), ED (1.7-1.8), OP hospial (8.4-9.4) office-visit
(11.2-12.6), and Other outpatient visits (18.9-20.5,) were similar across LOTs.
CONCLUSIONS: No significant variation in the PPPM costs of (IP, OP, ED, MBC oral
drugs, hormonal, radiology, or IV bisphosphonates) was oberved across four LOTs.
LOT costs differed for infused drugs, anti-emetics, and pain medication within this
MBC population. Further research is required to explore these variations.
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OBJECTIVES: To describe patterns of health care resource utilisation and associ-
ated costs for patients with advanced melanoma in the UK, Italy, and France.
METHODS: For patients receiving systemic treatment, or supportive care, hospi-
talisation, hospice care, and outpatient data were retrieved retrospectively from
advanced disease diagnosis until 1 May 2008 as part of a multicountry observa-
tional study (MELODY; Lorigan et al., ISPOR 2010). Costs were estimated by multi-
plying the utilisation level by unit cost. In an exploratory analysis, costs were
compared between individuals who died within one year of initiating first-line
treatment (short-term survivors) and those with 1 year follow-up (long-term
survivors). RESULTS: Hospitalisation costs were highest in France (€6262 per-per-
son compared with €3225 in the UK and €2486 in Italy), reflecting higher rates of
hospitalisation. In contrast, outpatient costs were highest in the UK (€782 per-
person, compared with €115 in France and €72 in Italy), reflecting both the highest
rate and frequency of outpatient visits and the highest cost per visit. While daily
hospice costs were lowest in the UK, frequency and duration of hospice care were
notably higher than in Italy or France, resulting in the highest total hospice costs
per-person. Hospitalisation rates were consistently higher during supportive care
compared with systemic therapy. It should be noted that roughly a third of patients
entered clinical trials and therefore could not be included in the analysis. In ex-
ploratory analysis, total costs were generally higher for long-term survivors, but
monthly per-patient costs were generally lower for long-term survivors, consistent
with a hypothesis that resource utilisation and costs do not necessarily increase
proportionally with extended survival. CONCLUSIONS: Total costs associated with
resource utilisation for advanced melanoma patients varied across countries.
Overall cost differences were due to differences in frequency and intensity of util-
isation patterns and variation in unit costs of health resources.
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OBJECTIVES: Data on economic burden of head & neck (H&N) and anal cancers in
Germany is scarce. Human papillomavirus (HPV) infection is likely to be responsi-
ble for 16% to 72% of H&N cancer, and 84% of anal cancer. This study aimed to
assess the annual management costs (hospitalisations, inpatient rehabilitations,
sick leaves) associated with these HPV-related cancers from the German Statutory
Health Insurance (SHI) perspective. METHODS: This study was based on the retro-
spective analysis of five German databases, which cover hospitalisations (German
Federal Statistical Office-Destatis), major categories of treatment such as surgery,
radiotherapy and medical (Institute for the Hospital Remuneration System-InEK),
inpatient rehabilitations (German Public Pension Insurance-DRV) and sick leaves
(Local-SHI-funds, Federal Ministry of Health). Associated number of cancers,
health care resource use, and costs were identified and extracted using ICD-10
codes (H&N cancer: C01-C06, C09-C14, C32; anal cancer: C21). The HPV-related
cancers total cost was estimated based on the percentage of each cancer and ana-
tomical site likely to be attributable to HPV. RESULTS: In 2008, 69,631 hospitalisa-
tions for H&N and anal cancers were reported (92% due to H&N cancer), whereas
the number of inpatient rehabilitations and sick leaves were 5,415 and 18,391,
respectively. The estimated total cost associated with HPV-related H&N and anal
cancers was €111 million, mainly represented by H&N cancer (74%). Hospitalisa-
tions, inpatient rehabilitations, and sick leaves, accounted for 82%, 4%, and 15% of
total HPV-related cost, respectively. CONCLUSIONS: The estimated annual cost of
HPV-related H&N and anal cancers contribute to a significant economic burden in
Germany, appearing to be as important as cost of HPV-related cervical cancer, and
should be considered when assessing health and economic benefits of HPV vacci-
nation in both genders. Furthermore, this cost is likely to be underestimated since
outpatient management cost is not included, and may be significant for these
cancers.
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OBJECTIVES: There are approximately 4 million of Hepatitis C Virus (HCV) carriers
in Europe. HCV infection is a leading cause of liver cirrhosis (LC), transplantation
(LT), and hepatocellular carcinoma (HCC). On the brink of new antiviral treatments
in France, we aimed at evaluating the 2009 hospital costs related to chronic hepa-
titis C.METHODS:All hospital stays with a B18.2 ICD-code were extracted from the
2009 hospital database and distributed in five groups: uncomplicated chronic hep-
atitis C, LC, HCC, LT, and unclassifiable. Costs were calculated using the French
medical information system (PMSI). RESULTS: A total of 27,258 stays were identi-
fied (15,482 patients): uncomplicated hepatitis C (42%), LC (41%), HCC (13%), LT (2%),
unclassifiable (2%). Mean length of stay was 6.1 and 28.7 days in medical and
surgical units respectively; 8,214 medical procedures for baseline/follow-up as-
sessments were carried out in patients with uncomplicated hepatitis, including
1,970 liver biopsies. Annual cost was estimated at 65,652,651€, including 47% for LC,
18% for HCC, and 19% for LT. The mean annual cost per patient increased from
1,049€ (uncomplicated hepatitis) to 4,748€ for LC, 6,513€ for HCC, and 40,152€ for LT
(expensive drugs excluded). Expensive drugs accounted for 7% of total costs in
public sector (95% of all stays), including 30% for cancer therapies, 33% for eryth-
ropoietins, 12% for anti-infection drugs and 11% for hemostasis. CONCLUSIONS:
This first analysis devoted to HCV infection of the French hospital national data-
base brings new and essential information. It shows that 84% of HCV-related hos-
pital costs are attributable to advanced liver diseases, and 19% to the 2% of patients’
recipients of a liver transplant. Together with more efficient therapies, enhancing
screening and access to treatment policy could substantially relieve the social
burden of HCV.
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OBJECTIVES: In Germany, breast cancer is the most frequent cancer. In 2007, 7.2%
of total German health care expenditure was spent on breast cancer. Despite, its
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